CD Equisearch
CD Equisearch is a venture capital firm based in Mumbai, India. This profile covers what we know about CD Equisearch and how founders can get in front of it in 2026.
CD Equisearch is one of the leading brokerage houses with a strong presence in the institutional and HNI broking segment.
- Location
- Mumbai, India
- Founded
- 2015
- Team size
- 51-100
How to pitch CD Equisearch
The founders who hear back from CD Equisearch lead with traction and a clear ask that matches its stage, not a generic mass email. Build a targeted, verified list, write a personalized note, and track who opens it, all in one place.
Connect with CD Equisearch
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise. How this data is built.
Cite this page
Round Funded. "CD Equisearch." Round Funded investor database, updated October 19, 2026.
Stable URL, it will not change: https://www.roundfunded.com/en/vc/cd-equisearch
Frequently Asked Questions
What is CD Equisearch?
CD Equisearch is a venture capital firm based in Mumbai, India. Round Funded tracks its focus, stage, and activity alongside thousands of active investors.
Where is CD Equisearch based?
CD Equisearch is based in Mumbai, India. You can reach out from anywhere with a pitch that matches its focus.
How do I contact CD Equisearch?
Unlock a verified email for CD Equisearch and reach out with a personalized pitch on Round Funded. We show only deliverable contacts, so your outreach does not bounce.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.